Citations

Clear

163 citation(s) found for "Sharp, H L".

Abstract 9887: Patient Selection for Ventricular Assist Device Therapy in the Elderly: Application of the HeartMate II Risk Score
Sundareswaran, Kartik S., Rogers, Joseph G, Kushwaha, Sudhir S. , Tatooles, Antone, Adamson, Robert M, Farrar, David J. , Cowger, Jennifer , Rogers, Joseph G, Pagani, Francis D. , Adamson, Robert M, Slaughter, Mark S.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 124 | Issue: suppl_21 | Pages: No page available

10.1161/circ.124.suppl_21.a9887 Get It

Introduction: Advanced age is a risk factor for poor outcomes following left ventricular assist device (LVAD) implant. A means of identifying elderly patients with acceptable mortality risk following LVAD surgery is not currently available. The HeartMate II (HMII) Risk Score (HMRS) was recently developed and validated, providing good risk discrimination for predicting survival in patients undergoing HMII implant. Independent survival predictors in the model included age and markers of renal function, coagulopathy and nutrition. We hypothesize that the HMRS will provide utility for risk stratification of the elderly LVAD candidate. Methods: Elderly patients (age >65 years) enrolled into the HMII Destination Therapy (DT) and Bridge to Transplant trials were selected for the study (n=444). Complete data for HMRS calculation was available in 98% (n=435). Preoperative patient HMRS was calculated according to the formula: HMRS = ln(1.29)*decade of age + ln(0.71)*Albumin + ln(1.37)*Cr + ln(1.86)*INR + ln(0.52)*LVAD Center Volume >=15 + ln(0.67)*Implant after 2007. Patients were trichotimized into high (HMRS >1.0), medium (HMRS 0.50-1.0), and low (HMRS <=0.50) risk categories (as previously defined in model development) based on HMRS. The primary endpoint was survival at 1 year following LVAD implant, estimated using Kaplan-Meier methods. Results: The mean cohort age was 71±4 years and 84% (n=372) had devices implanted for DT. The table shows the HMRS along with mean±stddev values for the score's components. All between-group differences were statistically significant (Kruskal-Wallis p<0.05), although differences in age were not clinically significant. Survival based on HMRS strata is shown in the figure. Patients in the low and medium risk groups had survivals >80% at 1 year following LVAD implant. Conclusions: The HMRS can be used to identify elderly patients with survivals comparable to that of the general LVAD population.
Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care
Walsh, Thomas , Kehl, Kenneth L. , Abel, Gregory A. , Sharp, Richard, Hantel, Andrew , Marron, Jonathan M. , Sharp, Richard R. , Van Allen, Eliezer M

Mayo Clinic

JAMA Network Open | March 28, 2024 | Volume: 7 | Issue: 3 | Pages: e244077

10.1001/jamanetworkopen.2024.4077 | PMID 38546644 Get It

Importance Artificial intelligence (AI) tools are rapidly integrating into cancer care. Understanding stakeholder views on ethical issues associated with the implementation of AI in oncology is critical to optimal deployment. Objective To evaluate oncologists’ views on the ethical domains of the use of AI in clinical care, including familiarity, predictions, explainability (the ability to explain how a result was determined), bias, deference, and responsibilities. Design, Setting, and Participants This cross-sectional, population-based survey study was conducted from November 15, 2022, to July 31, 2023, among 204 US-based oncologists identified using the National Plan &amp;amp; Provider Enumeration System. Main Outcomes and Measures The primary outcome was response to a question asking whether participants agreed or disagreed that patients need to provide informed consent for AI model use during cancer treatment decisions. Results Of 387 surveys, 204 were completed (response rate, 52.7%). Participants represented 37 states, 120 (63.7%) identified as male, 128 (62.7%) as non-Hispanic White, and 60 (29.4%) were from academic practices; 95 (46.6%) had received some education on AI use in health care, and 45.3% (92 of 203) reported familiarity with clinical decision models. Most participants (84.8% [173 of 204]) reported that AI-based clinical decision models needed to be explainable by oncologists to be used in the clinic; 23.0% (47 of 204) stated they also needed to be explainable by patients. Patient consent for AI model use during treatment decisions was supported by 81.4% of participants (166 of 204). When presented with a scenario in which an AI decision model selected a different treatment regimen than the oncologist planned to recommend, the most common response was to present both options and let the patient decide (36.8% [75 of 204]); respondents from academic settings were more likely than those from other settings to let the patient decide (OR, 2.56; 95% CI, 1.19-5.51). Most respondents (90.7% [185 of 204]) reported that AI developers were responsible for the medico-legal problems associated with AI use. Some agreed that this responsibility was shared by physicians (47.1% [96 of 204]) or hospitals (43.1% [88 of 204]). Finally, most respondents (76.5% [156 of 204]) agreed that oncologists should protect patients from biased AI tools, but only 27.9% (57 of 204) were confident in their ability to identify poorly representative AI models. Conclusions and Relevance In this cross-sectional survey study, few oncologists reported that patients needed to understand AI models, but most agreed that patients should consent to their use, and many tasked patients with choosing between physician- and AI-recommended treatment regimens. These findings suggest that the implementation of AI in oncology must include rigorous assessments of its effect on care decisions as well as decisional responsibility when problems related to AI use arise.
LACK OF EVIDENCE FOR HEPATITIS G VIRUS AND FULMINANT HEPATIC FAILURE IN CHILDREN:55
Pérez, R., Zein, Nizar N., Freese, Deborah K., Sharp, H L, Steers, Jeffery L., Persing, David H.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 23, 2024 | Volume: 25 | Issue: 4 | Pages: 456-456

10.1002/j.1536-4801.1997.tb01802.x Get It

No Evidence of Hepatitis G Virus in Fulminant Hepatic Failure in Children
Perez, Roger G., Zein, Nizar N., Freese, Deborah K., Perrault, Jean J., Steers, Jeffery L., Sharp, Harvey L., Persing, David H., Perez, R G, Perrault, Jean

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 23, 2024 | Volume: 28 | Issue: 4 | Pages: 400-403

10.1002/j.1536-4801.1999.tb02100.x Get It

ABSTRACTBackground:The cause of fulminant hepatic failure in children remains unknown, but a viral origin has been suspected in most cases. The recently discovered blood‐borne virus, hepatitis G, has been suggested as a possible causative agent.Method:Six consecutive children who underwent liver transplantation for fulminant hepatic failure were studied. The children were tested for hepatitis G virus antibodies and hepatitis G virus RNA by polymerase chain reaction after excluding other causes of fulminant hepatic failure.Results:No evidence of hepatitis G virus infection was found in these patients.Conclusion:Hepatitis G virus is unlikely to be a common cause of fulminant hepatic failure in pediatric patients from the upper midwestern United States.
Photophobia is associated with lower sleep quality in individuals with migraine: Results from the American Registry for Migraine Research (ARMR)
Sharp, Nina, Burish, Mark J. , Digre, Kathleen B. , Fani, Mahya, Lamp, Sophia J.

Mayo Clinic

No container title available | January 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3864442/v1 Get It

Abstract Background. Patients with migraine often have poor sleep quality between and during migraine attacks. Furthermore, extensive research has identified photophobia as the most common and most bothersome symptom in individuals with migraine, second only to headache. Seeking the comfort of darkness is a common strategy for managing pain during an attack and preventing its recurrence between episodes. Given the well-established effects of daily light exposure on circadian activity rhythms and sleep quality, this study aims to investigate the relationship between photophobia symptoms and sleep quality in a cohort of patients with migraine. Methods. A cross-sectional observational study was conducted using existing data extracted from the American Registry for Migraine Research (ARMR). Participants with a migraine diagnosis who had completed the baseline questionnaires (Photosensitivity Assessment Questionnaire (PAQ), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-2 (PHQ-2)), and selected questions of the ARMR Sleep questionnaire were included. Models were created to describe the relationship of photophobia and photophilia with various sleep facets, including sleep quality (SQ), sleep disturbance (SDis), sleep onset latency (SOL), and sleep-related impairments (SRI). Each model was controlled for age, sex, anxiety, and depression. Results. A total of 852 patients meeting the inclusion criteria were included in the analysis (mean age (SD) = 49.8 (13.9), 86.6% (n = 738) female). Those with photophobia exhibited significantly poorer sleep quality compared to patients without photophobia (p < 0.001). Photophobia scores were associated with SQ (p < 0.001), SDis (p < 0.001), SOL (p = 0.011), and SRI (p = 0.014), after controlling for age, sex, depression, and anxiety, signifying that higher levels of photophobia were associated with worse sleep-related outcomes. Conversely, photophilia scores were associated with better sleep-related outcomes for SQ (p < 0.001), SDis (p < 0.001), and SOL (p = 0.016). Conclusion. Results suggest that photophobia is a risk factor for sleep disorders in those with migraine. These results underscore the necessity for comprehensive and systematic investigations into the intricate interplay between photophobia and sleep to enhance our understanding and develop tailored solutions for individuals with migraine.
Qualitative Analysis of Decision to Pursue Electrical Brain Stimulation by Patients With Drug-Resistant Epilepsy and Their Caregivers
Balzekas, Irena , Richardson, Jordan , Lorence, Isabella , Lundstrom, Brian N. , Worrell, Gregory A. , Sharp, Richard R. , Richardson, Jordan P , Lundstrom, Brian Nils , Sharp, Richard R , Worrell, Gregory A

Mayo Clinic

Neurology Clinical Practice | January 18, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1212/cpj.0000000000200245 | PMID 38585236 Get It

145 INCREASED INCIDENCE OF SEVERE NON‐A/NON‐B HEPATITIS IN CHILDREN FROM THE UPPER MIDWEST, USA
Freese, D., Shamieh, I., Perrault, Jean, Sharp, H.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | January 3, 2024 | Volume: 19 | Issue: 3 | Pages: 365-365

10.1002/j.1536-4801.1994.tb11448.x Get It

A National Survey of Oncologists' Perspectives on the Ethical Implications of Artificial Intelligence in Cancer Care
Kehl, Kenneth L. , Walsh, Thomas , Abel, Gregory A. , Hantel, Andrew , Marron, Jonathan M. , Sharp, Richard R. , Van Allen, Eliezer M

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 2347-2347

10.1182/blood-2023-175030 Get It

Introduction Artificial Intelligence (AI) is an emerging technology that promises advancements across blood cancer discovery and care delivery. There are already FDA-approved uses of AI in hematology and oncology but few data available about its use or utility. Concerns have been raised over AI's potential biases, “explainability,” and who is responsible for its use. Oncologists' familiarity with AI and perspectives on these issues are not well known and are critical to understanding the ethical deployment of AI in blood cancer care. Methods From January to July 2023, we performed a national cross-sectional survey of practicing oncologists. A draft survey instrument was developed by a team with content and methodological expertise. Iterative refinement occurred through cognitive debriefing with 5 practicing hematologist/oncologists. The final instrument included 24 questions covering domains of AI familiarity, predictions, explainability, and responsibilities. A random sample of US oncologists was identified using the National Plan & Provider Enumeration System. Paper surveys were mailed with $25 incentivizing gift cards. Reminder letters and phone calls were used for non-responders with an electronic survey option provided. Responses were analyzed descriptively. X2 testing assessed bivariate associations between responses and participant practice setting, with odds ratios (OR) reported. Results Of 399 mailed surveys, 12 were undeliverable and 201 were completed for a response rate of 51.9%. Question missingness was &lt;1%. Participants were 63.2% White, 16.9% Indian Asian, 10.0% Eastern Asian or Pacific Islander, and 4.5% Black; 6.0% were Hispanic. They represented 37 states. The majority were male (63.7%), 40-59 years old (54.2%), and had no specific training in AI (52.2%); 68.2% had at least 11 years in practice and 29.9% practiced at a primary academic hospital. Questions assessing overall familiarity with and predictions related to AI are shown in Table 1. Those at primary academic hospitals were more likely to be familiar with radiology models (OR 2.82, p&lt;0.001) but not pathology, prognostic, or clinical decision models (all p&gt;0.05). They were more likely to predict that AI would improve side effect management (OR 2.01, p=0.03) and end-of-life decision making (OR 2.07, p=0.02). High proportions of respondents thought that AI prognostic (67.1%) and clinical decision models (62.1%) needed to be explainable by clinicians and researchers to be used in clinic. When posed with a scenario where an FDA-approved AI model selects a different regimen than the oncologist planned to propose (Figure 1), the largest proportion reported they would present both options and let the patient decide (37.3%). Of those recommending a regimen, respondents from primary academic hospitals more frequently recommend the AI-generated regimen (56.1%), while respondents from elsewhere recommended their original regimen (69.0%; OR 2.85, p=0.007). Acceptability of some direct-to-patient AI model applications is shown in Table 1. A majority of respondents (90.5%) thought that AI developers should be responsible for medico-legal problems caused by AI use; 47.8% thought that physicians using the tool should be responsible. Though most (76.1%) agreed that it was oncologists' responsibility to protect patients from biased AI tools, few (27.3%) were confident in their ability to identify how representative the data used in an AI model was relative to the population with that cancer (including 66.7% of those who agreed it was oncologists' responsibility). More respondents thought that patients should need to consent to the use of AI tools in cancer treatment decisions (81.1%) than cancer diagnosis (55.7%); those from primary academic hospitals were less likely to respond that patients should consent for treatment or diagnosis (OR 0.43, p=0.02 and OR 0.44, p=0.009). Conclusions In this national survey of oncologists' views on AI, there was optimism about its impact on care with notable caveats related to end-of-life care, patient trust, and care disparities. Despite many approving use of AI models too complex for patients to explain, a substantial proportion deferred to patient choice when AI and physician recommendations differed. There was also dissonance between accepting responsibility to protect patients from bias and respondents' self-perceived ability to do so.
P1.1: Laryngotracheal transplant: Patient and caregivers’ beliefs and perceptions
Grandjean, Danielle, Cotton-Zacharias, Stephanie, Weir, Isabel B. , Lott, David G. , Sharp, Richard R. , Curtis, Susan

Mayo Clinic

Transplantation | October 13, 2023 | Volume: 107 | Issue: 10S1 | Pages: 78-78

10.1097/01.tp.0000993444.58789.55 Get It

Introduction to concept inventories for medical physics education
Cetnar, Ashley J. , Besemer, Abby, Bry, Victoria, Buckey, C, Burmeister, Jay , Rodrigues, Anna , Schubert, Leah , Speidel, Michael A. , Sutlief, Steven , Yu, Amy S. , Buckey, Courtney R, Yu, Amy Shu-Jung , Bry, Victoria N.

Mayo Clinic

Journal of Applied Clinical Medical Physics | August 30, 2023 | Volume: 24 | Issue: 10 | Pages: No page available

10.1002/acm2.14130 | PMID 37646429 Get It

AbstractConcept inventories are multiple choice exams designed with the intention to test core concepts on specific subjects and evaluate common misconceptions. These tests serve as a useful tool in the classroom to assess value added by the instructor's educational methods and to better understand how students learn. They can provide educators with a method to evaluate their current teaching strategies and to make modifications that enhance student learning and ultimately elevate the quality of medical physics education. The use of concept inventories in introductory college physics courses revealed important gaps in conceptual understanding of physics by undergraduate students and motivated a shift of physics teaching towards more effective methods, such as active learning techniques. The goal of this review is to introduce medical physicists to concept inventories as educational evaluation tools and discuss potential applications to medical physics education by development through multi‐institutional collaboration.